FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078662350> ?p ?o ?g. }

• W2078662350 endingPage "1047" @default.
• W2078662350 startingPage "1039" @default.
• W2078662350 abstract "Background: Renin–angiotensin system (RAS) blockade with ACE inhibitor and/or angiotensin receptor blocker therapy can lead to increased potassium levels, hence the need to assess dual blockade involving a direct renin inhibitor. Here we report the results of a pre-planned 6-month interim analysis of a long-term, open-label study examining the safety, tolerability and efficacy of the aliskiren/valsartan 300/320-mg combination in patients with hyper­tension.Methods: A total of 601 patients with hyper­tension (msDBP ≥ 90 and < 110 mmHg) received a combination of aliskiren/valsartan 150/160 mg for 2 weeks followed by forced titration to aliskiren/valsartan 300/320 mg once daily for a targeted duration of 52 weeks. Optional hydrochlorothiazide (HCTZ) addition was allowed from week 8 for inadequate BP control (≥ 140/90 mmHg). The primary objective was to assess the safety of combination therapy; potassium elevations were a pre-defined safety outcome. BP was measured at regular intervals during the study.Results: At the 6-month cut-off date, 512 patients (85.2%) were still ongoing with study treatment, and 192 patients had received at least one dose of HCTZ add-on during this period. Combination therapy was generally well-tolerated; the most commonly reported adverse events were headache (7.5%), dizziness (7.3%) and nasopharyngitis (7.2%). Ten patients (2.5%) receiving aliskiren/valsartan and two patients (1.0%) receiving aliskiren/valsartan/HCTZ had serum potassium elevations > 5.5 mmol/L. Only one patient (0.2%) exhibited potassium levels ≥ 6.0 mmol/L during this period and the patient was treated with aliskiren/valsartan. Mean msSBP/DBP reductions of 22.3/14.4 mmHg were observed at 6-month endpoint (LOCF analysis) and 73.4% of patients achieved BP control (< 140/90 mmHg; LOCF).Conclusions: Although lack of an active comparator group is a limitation of the study, our findings show that long-term treatment with the aliskiren/valsartan 300/320-mg combin­ation provided clinically significant BP lowering, was well-tolerated and was associated with a very low rate of potassium elevations in patients with hyper­tension." @default.
• W2078662350 created "2016-06-24" @default.
• W2078662350 creator A5026083147 @default.
• W2078662350 creator A5029089901 @default.
• W2078662350 creator A5038033608 @default.
• W2078662350 creator A5040800792 @default.
• W2078662350 creator A5053427557 @default.
• W2078662350 creator A5076355849 @default.
• W2078662350 creator A5083444792 @default.
• W2078662350 date "2008-02-27" @default.
• W2078662350 modified "2023-09-22" @default.
• W2078662350 title "Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis" @default.
• W2078662350 cites W1974906889 @default.
• W2078662350 cites W1975399478 @default.
• W2078662350 cites W1994332748 @default.
• W2078662350 cites W1997087913 @default.
• W2078662350 cites W2013154098 @default.
• W2078662350 cites W2027617419 @default.
• W2078662350 cites W2037521161 @default.
• W2078662350 cites W2037627800 @default.
• W2078662350 cites W2063358281 @default.
• W2078662350 cites W2078374154 @default.
• W2078662350 cites W2085746985 @default.
• W2078662350 cites W2093767567 @default.
• W2078662350 cites W2096955111 @default.
• W2078662350 cites W2098780362 @default.
• W2078662350 cites W2106648861 @default.
• W2078662350 cites W2107914594 @default.
• W2078662350 cites W2118772456 @default.
• W2078662350 cites W2122088193 @default.
• W2078662350 cites W2124013021 @default.
• W2078662350 cites W2143144750 @default.
• W2078662350 cites W2152094259 @default.
• W2078662350 cites W2168907840 @default.
• W2078662350 cites W2171818587 @default.
• W2078662350 cites W2172086404 @default.
• W2078662350 doi "https://doi.org/10.1185/030079908x280581" @default.
• W2078662350 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18307835" @default.
• W2078662350 hasPublicationYear "2008" @default.
• W2078662350 type Work @default.
• W2078662350 sameAs 2078662350 @default.
• W2078662350 citedByCount "44" @default.
• W2078662350 countsByYear W20786623502012 @default.
• W2078662350 countsByYear W20786623502013 @default.
• W2078662350 countsByYear W20786623502014 @default.
• W2078662350 countsByYear W20786623502020 @default.
• W2078662350 crossrefType "journal-article" @default.
• W2078662350 hasAuthorship W2078662350A5026083147 @default.
• W2078662350 hasAuthorship W2078662350A5029089901 @default.
• W2078662350 hasAuthorship W2078662350A5038033608 @default.
• W2078662350 hasAuthorship W2078662350A5040800792 @default.
• W2078662350 hasAuthorship W2078662350A5053427557 @default.
• W2078662350 hasAuthorship W2078662350A5076355849 @default.
• W2078662350 hasAuthorship W2078662350A5083444792 @default.
• W2078662350 hasConcept C126322002 @default.
• W2078662350 hasConcept C126894567 @default.
• W2078662350 hasConcept C168563851 @default.
• W2078662350 hasConcept C197934379 @default.
• W2078662350 hasConcept C198710026 @default.
• W2078662350 hasConcept C2776999253 @default.
• W2078662350 hasConcept C2777387769 @default.
• W2078662350 hasConcept C2778375690 @default.
• W2078662350 hasConcept C2779838083 @default.
• W2078662350 hasConcept C2780361556 @default.
• W2078662350 hasConcept C61943457 @default.
• W2078662350 hasConcept C71924100 @default.
• W2078662350 hasConcept C84393581 @default.
• W2078662350 hasConcept C98274493 @default.
• W2078662350 hasConceptScore W2078662350C126322002 @default.
• W2078662350 hasConceptScore W2078662350C126894567 @default.
• W2078662350 hasConceptScore W2078662350C168563851 @default.
• W2078662350 hasConceptScore W2078662350C197934379 @default.
• W2078662350 hasConceptScore W2078662350C198710026 @default.
• W2078662350 hasConceptScore W2078662350C2776999253 @default.
• W2078662350 hasConceptScore W2078662350C2777387769 @default.
• W2078662350 hasConceptScore W2078662350C2778375690 @default.
• W2078662350 hasConceptScore W2078662350C2779838083 @default.
• W2078662350 hasConceptScore W2078662350C2780361556 @default.
• W2078662350 hasConceptScore W2078662350C61943457 @default.
• W2078662350 hasConceptScore W2078662350C71924100 @default.
• W2078662350 hasConceptScore W2078662350C84393581 @default.
• W2078662350 hasConceptScore W2078662350C98274493 @default.
• W2078662350 hasIssue "4" @default.
• W2078662350 hasLocation W20786623501 @default.
• W2078662350 hasLocation W20786623502 @default.
• W2078662350 hasOpenAccess W2078662350 @default.
• W2078662350 hasPrimaryLocation W20786623501 @default.
• W2078662350 hasRelatedWork W2037521161 @default.
• W2078662350 hasRelatedWork W2049351459 @default.
• W2078662350 hasRelatedWork W2067519483 @default.
• W2078662350 hasRelatedWork W2078662350 @default.
• W2078662350 hasRelatedWork W2080039021 @default.
• W2078662350 hasRelatedWork W2081422047 @default.
• W2078662350 hasRelatedWork W2084697582 @default.
• W2078662350 hasRelatedWork W2156023625 @default.
• W2078662350 hasRelatedWork W2315876449 @default.
• W2078662350 hasRelatedWork W95079111 @default.
• W2078662350 hasVolume "24" @default.

• next